Navigation Links
Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
Date:11/20/2011

Treatment with dexpramipexole a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine. Some preliminary results of the study were presented at the 2009 International Symposium on ALS/MND and the 2010 American Academy of Neurology annual meeting.

"Today there are only two FDA-approved drugs used to treat ALS riluzole, which extends life about 10 percent, and Nuedexta, which treats the emotional instability that characterizes ALS and other neurological disorders," says Merit Cudkowicz, MD, director of the Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, lead author of the study. "We need more therapies to slow, halt and ultimately reverse the course of disease and also therapies to treat the symptoms."

Also known as Lou Gehrig's disease, ALS is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. Death of these nerve cells stops the transmission of neural impulses to muscle fibers, leading to weakness, paralysis and usually death from respiratory failure. Mitochondrial dysfunction is among several factors believed to underlie nerve cell death. Initially developed by Knopp Biosciences of Pittsburgh, dexpramipexole appears to protect neurons from mitochondrial dysfunction.

Several investigators from Knopp, which sponsored the study reported in the current article, collaborated with Cudkowicz and the Northeast ALS Consortium on the trial. Co-founded and co-directed by Cudkowicz, the Northeast ALS Consortium includes over 100 clinical sites throughout North America that work collaboratively on clinical trials and has established the infrastructure necessarily to qui
'/>"/>

Contact: Mike Morrison
mdmorrison@partners.org
617-724-6425
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 ... weight are at risk later in life of having smaller, ... for heart disease, according to a pair of new studies. ... disadvantages, researchers in both studies -- published online Sept. 1 ... be overcome. Education appeared to negate the potential harmful ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 2014 National law firm, ... has filed an application for attorneys’ fees and ... action litigation brought over Flushmate flushing mechanisms. In ... Counsel in this litigation includes Birka-White Law Offices; ... Partners, LLP; Levin Fishbein, Sedran & Berman, LLP; ...
(Date:9/2/2014)... Lseat.com is one of the most popular suppliers of useful ... items; no professional installation is required. Customers do not need ... over the cars’ seats. That can save plenty of time ... various kinds of practical covers. , In addition, it ... seat covers . Also, the company has launched a special ...
(Date:9/2/2014)... 2014 The global market for peripheral ... by 2020, growing at an estimated CAGR of 7.2% ... by Grand View Research, Inc. Peripheral vascular devices such ... are used for treating peripheral arterial or coronary arterial ... in arteries. These devices are used to decrease the ...
Breaking Medicine News(10 mins):Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 2Health News:Preterm or Small Birth Tied to Long-Term Risks to Heart, Brain 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 2Health News:A Proposed Order Has Been Submitted in A Class Action Law Suit Brought Over Flushmate Toilets, Parker Waichman Announces 3Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 2Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 3Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 4Health News:Peripheral Vascular Devices Market By Product (Peripheral Vascular Stents, PTA Guidewires, Atherectomy Devices) Is Expected To Reach USD 8,918.8 Million By 2020 5
... Legislation Introduced to Fund Lung Cancer ResearchBOSTON, Jan. ... Senator Susan Fargo (D-3rd Middlesex), the Senate Chair ... once again introducing comprehensive legislation that creates a ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for positive ...
... (Nasdaq: ROCM ) today announced that Covidien ... litigation which Rochester Medical,filed on March 16, 2004 against ... L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing,Partners L.P. ... of the settlement, Rochester Medical, represented by The,Lanier Law ...
... festival in Park,City, Utah, usually known for power lunches, will ... full-service fitness center, called,the "G Gym." Actors Eliza Dushku ... of the many celebrities to snatch up appointments with top,Hollywood ... or $1,000 for,charity, up to $20,000. , ...
... YORK, Jan. 15 On Tuesday, February 3, 2009, ... The Fifth Annual Beyond Beauty Gala to benefit The ... genetic research and awareness for Obsessive-Compulsive Disorder (OCD). ... evening,s event will be held at The Union League ...
... Package and House Vote to Expand Child Health InsuranceTUCSON, Ariz., ... Corporation (Nasdaq: PRSC ) today provided an update ... package being sought by President-elect Barack Obama as well as ... insurance. The economic stimulus package under discussion includes aid ...
... Roxane Laboratories, Inc.,announced today the approval of their ... 500mg, 750mg, 1000mg, and Oral Solution,100mg/mL. The product ... nationwide. , Roxane Laboratories, ... UCB, Inc.,s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) ...
Cached Medicine News:Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3Health News:Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution 2
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: